Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
about
Towards tumor immunodiagnosticsTumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast CancerTumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune TargetingThe Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-AnalysisExercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and ProgressionThe fate of chemoresistance in triple negative breast cancer (TNBC)A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All CancersRelevance of tumor-infiltrating lymphocytes in breast cancerCurrent Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast CancerClinical significance of tumor-infiltrating lymphocytes in breast cancerStrategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyondTailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid ClassesA Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage ResponsImmune DNA signature of T-cell infiltration in breast tumor exomes.Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Precision medicine in breast cancer: reality or utopia?The immune microenvironment of breast ductal carcinoma in situ.Novel therapeutic strategies in the treatment of triple-negative breast cancer.Somatic mutations in leukocytes infiltrating primary breast cancers.Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.Histological Analysis of γδ T Lymphocytes Infiltrating Human Triple-Negative Breast Carcinomas.Tumor Infiltrating Lymphocytes - The Next Step in Assessing Outcome and Response to Treatment in Patients with Breast CancerGene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response.The expression of CXCL13 and its relation to unfavorable clinical characteristics in young breast cancerImmunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study.The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients.Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer.Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating LymphocytesIdentification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancerPlatelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapyPrognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC).An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer.Antibody-supervised deep learning for quantification of tumor-infiltrating immune cells in hematoxylin and eosin stained breast cancer samples.
P2860
Q26738691-64A8DC1D-53B7-4003-9EF2-9CF81D33A837Q26745446-D5F58B9E-34BE-4BEC-8E7D-98689CBA24DEQ26747792-BBEEB8F3-321E-434A-872F-D486B231DC6BQ26748691-2616CA01-B4A3-424E-9A85-5529A614D53DQ26775189-0FB032D5-4666-45FE-8F5F-5D2EFDB28F95Q26775232-28D221E5-AAD2-417B-B756-EE59BF504142Q26777111-8239A022-DA5A-432C-A364-B7A7D8D46AD9Q26795598-B697C033-551D-47D0-8F09-A2946A48D614Q26798074-1604BD40-8712-4270-8EA7-9721F5164713Q28070214-3184999A-5A88-4AFD-AA3C-7738604ECF4BQ28077815-F88A1C94-34BA-4AD2-8322-9C758F22CF98Q28085062-8A09F980-3DD2-4F2D-B125-D16615C1AFB3Q28554412-42C36440-CFC6-469D-8EE0-EFD8EF5B8B9EQ30253017-B569F337-6575-45B6-BCDA-6FB14AE37BB8Q30377226-7B67D400-5AF9-448F-9C1C-5F6125EE28CCQ33441772-91303D41-A433-4CAC-941E-0C0776383715Q33591876-99D708D2-D449-4995-B612-8A1A2F2BA71DQ33769821-9341C1DE-ABC1-4D9C-8266-5FF5B00A517CQ33809114-258F7BDB-DE2A-45ED-A1AF-643DB7B67DF8Q33834968-572E8213-8A70-4A3F-84EE-D219C6A2EE65Q33887682-2B48AE1C-0E05-406D-BC4F-B09D025FC35AQ33914716-67E13089-FE3B-4560-9BB6-E79C76602816Q33915057-AFF5D33C-FFCA-4CB2-9D21-BF2D952C588AQ34547261-5059F14C-1194-4568-978E-5D157E961C9BQ34668723-654B9408-4988-41BF-B9AC-CE5FFAE8BFBDQ35149726-442BDCCF-D618-4472-B42D-2E5FF8CCABD0Q35314135-8A186868-3596-4276-B65D-C7F4A2B3782FQ35754593-DD759E68-65FB-4F28-B765-69544944664EQ35807180-E4830D27-A4B1-4040-A26C-32F698E97CD6Q35845330-F64DAB45-DD5E-4DF4-A184-52801A5CC956Q35879081-EBC338A1-22F7-4416-8577-7D2562BA1D20Q35922142-F0E1B37D-71F1-492B-A148-A9BBDCE77027Q35958861-BFBB7E57-32F4-4DCF-B54A-979B31960573Q35992815-9F585F9A-0A86-4433-BE19-96FB6E4831DFQ36028749-C5D05C71-2E5E-4627-997E-E45A2F706812Q36030405-15B38F08-B50D-476C-A958-536C069E131EQ36054418-B7AB90F2-FCD9-4E9D-B719-8CEED630C93DQ36060283-6D1AE219-D086-4B1B-B979-B7F2D1B48078Q36085118-6480CD55-A665-4D4A-8EE5-AC2CA33361CEQ36149520-87CCBC09-40FB-4639-89C8-0D09F4214C6D
P2860
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Prognostic value of tumor-infi ...... ials: ECOG 2197 and ECOG 1199.
@ast
Prognostic value of tumor-infi ...... ials: ECOG 2197 and ECOG 1199.
@en
Prognostic value of tumor-infi ...... ials: ECOG 2197 and ECOG 1199.
@nl
type
label
Prognostic value of tumor-infi ...... ials: ECOG 2197 and ECOG 1199.
@ast
Prognostic value of tumor-infi ...... ials: ECOG 2197 and ECOG 1199.
@en
Prognostic value of tumor-infi ...... ials: ECOG 2197 and ECOG 1199.
@nl
prefLabel
Prognostic value of tumor-infi ...... ials: ECOG 2197 and ECOG 1199.
@ast
Prognostic value of tumor-infi ...... ials: ECOG 2197 and ECOG 1199.
@en
Prognostic value of tumor-infi ...... ials: ECOG 2197 and ECOG 1199.
@nl
P2093
P2860
P50
P356
P1476
Prognostic value of tumor-infi ...... ials: ECOG 2197 and ECOG 1199.
@en
P2093
Edith A Perez
George W Sledge
Joseph A Sparano
Lawrence N Shulman
Lori Goldstein
Molin Wang
Nancy E Davidson
Robert J Gray
Silvana Martino
Sunil S Badve
P2860
P304
P356
10.1200/JCO.2013.55.0491
P407
P577
2014-09-01T00:00:00Z